Epizyme’s Tazemetostat Granted Orphan Drug Designation for Malignant Rhabdoid Tumors by U.S. FDA

Epizyme, Inc., a Cambridge-based clinical stage biopharmaceutical company creating novel epigenetic therapeutics for cancer patients, announced that the U.S. FDA has granted orphan drug status to the company's first-in-class EZH2 inhibitor, tazemetostat,...

Non-surgical Prescription Vision Aid Cleared by FDA for Use by People Who are Profoundly...

FDA granted approval for marketing of a new device (BrainPort V100) that when used along with other assistive devices, like a cane or guide dog, can help orient people who are...

RGX-104 Received Another Orphan Drug Designation from U.S FDA for Treatment of Malignant Melanoma...

RGX-104, an investigational drug being developed by Rgenix, Inc., a biotechnology company based in New York, NY received another Orphan Drug Designation (ODD) from the U.S. FDA for the treatment of...

SPOTLIGHT

STAY CONNECTED

Twitter LinkedIn 

WUXI NEWS

WuXi AppTec Expands Site in the United States for Drug Development...

We are pleased to announce the grand opening of WuXi AppTec's expanded Laboratory Testing Division (LTD) facility in New Jersey. The expansion will double total...